Deal Roundup: CVC seals $925m Therakos buyout, GenNx360 sells GenServe to Aurora Capital

CVC has agreed to buy the Therakos business of global pharmaceuticals major Mallinckrodt in a $925m deal. Therakos is a fully integrated extracorporeal photopheresis delivery system for autologous immunomodulatory therapy, used to treat a range of immune-related diseases. CVC said it intends to make additional investments in the continued research, development, indication expansion and geographic …